Belvedere Trading’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-233
Closed -$2.75K 1569
2022
Q4
$2.75K Buy
+233
New +$2.66K ﹤0.01% 1025
2022
Q1
Sell
-3,070
Closed -$129K 674
2021
Q4
$129K Buy
3,070
+1,377
+81% +$85.9K 0.01% 266
2021
Q3
$146K Buy
+1,693
New +$124K ﹤0.01% 296

Other funds holding DMK

Belvedere Trading's DMK Position: Q1 2023 in Review

Belvedere Trading sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2023, closing a stake of 22 shares — an estimated $260 sold.

Belvedere Trading first reported a position in DMK in Q4 2022 and held it in 1 quarter. The position peaked at $260 in Q4 2022. 47 funds tracked by Wall St. Rank hold DMK as of Q1 2023.

  • Belvedere Trading reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 22 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2023, an estimated $260.
  • Belvedere Trading first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2022 and held it in 1 quarter.
  • Belvedere Trading's DMK Pharmaceuticals Corporation Common Stock position peaked at $260 in Q4 2022.
  • 47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.